TITLE PAGE

Age-Modulated Immuno-Metabolic Proteome Profiles of Deceased Donor

Kidneys Predict 12-Month Posttransplant Outcome

Authors: Philip D Charles[1,2†], Sarah Fawaz[3,4*], Rebecca H Vaughan[3,4*], Simon Davis[2], Priyanka

Joshi[3], Iolanda Vendrell[2], Ka Ho Tam[5], Roman Fischer[2], Benedikt M Kessler[2], Edward J

Sharples[6], Alberto Santos[1,7,8], Rutger J Ploeg[3,4], Maria Kaisar[3,4†]

Affiliations:

[1]Big Data Institute, Nuffield Department of Medicine, University of Oxford; Oxford, United

Kingdom.

[2]Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine,

University of Oxford; Oxford, United Kingdom.

[3]Research and Development, NHS Blood and Transplant; Bristol & Oxford, United Kingdom.

[4]Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre, University

of Oxford; Oxford, United Kingdom.

[5]Engineering Department, University of Oxford; United Kingdom.

[6]University Hospital Oxford; Oxford, United Kingdom.

[7]Center for Health Data Science, University of Copenhagen; Copenhagen, Denmark.

[8]Novo Nordisk Foundation Center for Protein Research, University of Copenhagen;

Copenhagen, Denmark.

*These authors contributed equally.

†Corresponding authors. Email: philip.charles@ndm.ox.ac.uk; maria.kaisar@nds.ox.ac.uk

Keywords:

ABSTRACT

Background. Organ availability limits kidney transplantation, the best treatment for end-

stage kidney disease. Deceased donor acceptance criteria have been relaxed to include older

donors with higher risk of inferior posttransplant outcomes. Donor age, although significantly

correlates with transplant outcomes, lacks granularity in predicting graft dysfunction. Better

characterization of the biological mechanisms associated with deceased donor organ damage and

specifically predictive of transplant outcome in recipients is key to developing new assessment

criteria for donor kidneys and developing function-preserving interventions.

Methods. 185 deceased donor pretransplant biopsies with clinical and demographic

donor and recipient metadata were obtained from the Quality in Organ Donation biobank

(QUOD), selected on the basis of 12-month paired posttransplant function and deep proteomic

profiles acquired by mass spectrometry. Using a $2/3^{rd}$:$1/3^{rd}$ training:test data split, sampling

equally across posttransplant function, we applied machine learning feature selection followed

by protein-wise relaxed LASSO regression modeling, assessing the performance of the final set

of protein models on the test data. Western blotting validated protein changes, and the biological

relevance of the final set of protein models was externally validated by contextualization against

a published dataset of human healthy and disease kidney transcriptomes.

Results. Our analysis revealed 144 proteins carrying outcome-predictive information, all

of which showed donor-age modulated associations with posttransplant function, as opposed to

age and protein/gene effects being independent terms. Observed associations with inflammatory,

metabolic, protein processing and cell cycle pathways suggest biological targets for possible

interventions pretransplant. Contextualization of our results against external spatial

transcriptomic data suggest a sub-nephrotic spatial localization of the predictive signal.

Conclusions. Integrating kidney proteome information with clinical metadata enhances

the resolution of donor kidney quality stratification, and the highlighted biological mechanisms

open new research directions in developing predictive models and novel interventions during

donor management or preservation to improve kidney transplant outcome.

SIGNIFICANCE STATEMENT

Currently, organ quality assessment pretransplant relies on key factors such as donor age or

clinical information, these lack granularity in depicting graft susceptibility and capacity to

function posttransplant. A high-resolution proteomic profiling of 185 pretransplant biopsies of

kidneys with known posttransplant function and complete metadata was performed. Integration

of donor kidney proteomes with 56 clinical metadata variables using regularized regression

modelling resulted in enhancing the resolution of donor kidney quality stratification. Immuno-

metabolic and catabolic processes contributed to donor kidney susceptibility and worse

transplant outcomes in an age modulated pattern, validated by western blotting. Comparison of

kidney proteomes with a recent transcriptomics dataset of healthy and diseased kidneys provide

an additional special single cell resolution to the findings of this study.

INTRODUCTION

Kidney transplantation is the optimal treatment for end-stage kidney disease. Compared to dialysis, transplantation increases life-expectancy, improves quality of life and is cost-effective. Limited availability of suitable donor kidneys impedes treatment of chronic kidney disease, and often prolongs dialysis, increasing morbidity and mortality. Deceased donor organ shortages, living donation decline in some countries and emerging ageing populations drive increased utilization of older deceased donor kidneys, now comprising more than half of offered organs[1,2].

Ageing associates with time-dependent decline of organ function, evidenced in kidneys by histologic lesions, such as tubular atrophy, interstitial fibrosis, glomerulosclerosis, and arteriosclerosis. Older kidneys demonstrate fewer functioning glomeruli, less renal mass, podocyte dysfunction, and impaired cellular repair[3]. Glomerular diseases are more common and associated with worse outcomes in older patients[4]. Age accelerates the transition from Acute Kidney Injury (AKI) to chronic injury[5] and is an independent risk factor of graft dysfunction and loss for deceased donor kidneys[6]; furthermore, older donors are more likely to suffer from additional risk factors such as diabetes, hypertension or cardiovascular disease.

Donor age is incorporated in clinical scoring algorithms to inform kidney allocation decisions[7,8], but is insufficient to consistently predict transplant outcomes. Current front-line models incorporating further clinical factors such as terminal serum creatinine, history of hypertension and diabetes[8,9] show consistent performance across demographics but lack granular predictive accuracy[10].

Molecular analyses of biopsies plausibly offer higher resolution assessment of organ state; but require 'big picture' understanding of mechanisms associated specifically with poor

outcome, rather than immediate (but potentially recoverable) acute injury. Deceased donors are

frequently assessed as having sustained damage (i.e. AKI) based on serum creatinine levels[11],

however this metric poorly associates with longer term outcomes[11–14].

Mass spectrometry (MS) proteomic studies can provide such a 'big picture', but have

heretofore lacked cohort capacity to represent demographic diversity[15]. Advances in high-

throughput techniques[16] now allow sensitivity and depth without sacrificing throughput capacity.

Developments in machine learning and nonlinear regression analyses furthermore offer tools to

extract maximal knowledge from limited size experimental cohorts, with applications in disease

staging, disease recurrence prediction, treatment response monitoring, and biomarker

identification[17,18].

Integration of deep proteomic profiles with heterogenous clinical and demographic

factors using modern statistical tools can empower the next steps toward precision medicine[19].

Here, we benefit from the granularity provided by our MS-based proteomic profiling to report

age- and immunometabolism-related proteomic signatures in pre-implantation kidney biopsies

associated with transplant outcomes.

METHODS

Study Design

Deceased donor pre-transplantation kidney biopsies (n=186; 1 sample excluded during

data processing) were obtained from the Quality in Organ Donor (QUOD) biobank, a national

multi-center UK wide bioresource of deceased donor clinical samples acquired during donor

management and organ procurement. Biopsies were obtained from Donation after Brain Death

(DBD) donors and Donation after Circulatory Death (DCD) donors at the back table immediately

after kidney procurement.

Selection of biopsies was based on paired 12-month post-transplant outcomes. To

minimize the impact of recipient factors, we only included kidneys for which the contralateral

kidney was transplanted with similar outcome. Kidneys were selected to cover the outcome

continuum i.e. the range of estimated Glomerular Filtration Rate (eGFR) in the recipient at 12

months posttransplant (henceforth, 'eGFR12'), from primary non-function to eGFR>80

ml/min/1.73 m^2, excluding pediatric donors. Samples were linked to corresponding donor and

recipient demographic and clinical metadata, provided by NHS Blood and Transplant National

Registry.

Study Approval and Ethics statement

Informed consent from donor families was obtained prior to sample procurement.

Collection of QUOD samples and research ethics approval was provided by QUOD

(NW/18/0187).

Protein Extraction from Renal Tissue Specimens

Deceased donor biopsies were procured, handled and stored according to consistent,

predefined collection protocols designed to minimize pre-analytical variability. Donor kidney

biopsies were collected ex situ immediately after flush-out and procurement of the kidney in the

donor hospital on the back-table. Biopsies were obtained from the upper pole of the donor kidney

cortex during back table preparation, using a 23mm needle biopsy gun. The obtained biopsies

were divided in two, with one half stored in RNAlater (Thermo Scientific, Illinois, USA), then

liquid nitrogen and the other half stored in formalin.

RNAlater biopsy samples were homogenized in RIPA buffer (89900, Thermo Scientific,

Illinois, USA) with protease and phosphatase inhibitor cocktail (1861280, Thermo Scientific,

Illinois, USA) using a bead beater (Biorad, Hertfordshire, UK) at 6500rpm for three cycles of 40

seconds with intermediate cooling on wet ice between cycles. Biopsy protein concentration was

determined using a Pierce Bicinchoninic Acid protein assay kit (23227 Thermo Scientific,

Illinois, USA).

In-Solution Trypsin Digestion

50 µg of protein homogenates were prepared. Disulfide bonds were reduced by adding

200 mM of DTT (Sigma) to a final concentration of 5 mM for 60 mins at room temperature. Free

cysteine residues were alkylated by adding 200 mM of iodoacetamide (Sigma) to a final

concentration of 20 mM and incubated for 60 mins at RT in the dark.

The samples were topped up to 200 µl with 6 M urea, 100 mM TrisHCl pH 8.5.

Methanol/chloroform protein precipitation was used to remove detergents before tryptic

digestion. In brief, 600 µl of Methanol and 150 µl of Chloroform were added and mixed. Then

450 µl of MilliQ-H2O was added and then centrifuged for 1min at 12,000 g. The upper aqueous

layer was carefully removed without disturbing formed protein pellets between layers and 450 µl

of Methanol was added and then centrifuged at 12,000 g for 5 min. The supernatant was removed

and the protein pellets resuspended in 50 µl of 6 M Urea, 100 mM TrisHCl, pH 8.5. Urea

concentration was reduced to 1 M by adding 250 µl of MillQ-H2O. Samples were digested at 37

°C overnight with Trypsin added at a 1:50 ratio (trypsin:protein). Tryptic peptides were acidified

and purified using Sep-Pak C18 cartridges (WAT020515, Waters, Wilmslow, UK) and dried by

Speed Vac centrifugation. Pellets were resuspended in 80 µl of resuspension buffer A (98 %

MilliQ-H2O, 2 % acetonitrile 0.1 % formic acid) for LC-MS/MS analysis.

Mass Spectrometry Analysis

Generation of Fractionated Pool for Spectral Library Reference

A highly fractionated spectral library was generated as a standard reference for the subsequent analysis of individual samples. To create this spectral library, a pool sample was prepared by combining 2 µl of each tryptic digest sample prepared above. Fractionation of the pooled sample was performed using offline high-pH reverse-phase HPLC on an XBridge BEH C18 XP column (3 × 150 mm, 2.5 µm pore size, Waters no. 186006710) over a 100-minute gradient (Buffer A: water, pH10 with ammonium hydroxide. Buffer B: 90 % acetonitrile, 10 % water, pH10 with ammonium hydroxide) with fractions collected every 2 minutes. The fractions of the pool sample for the spectral library were analyzed by nanoLC-MS/MS using a Dionex Ultimate 3000 using a 75 µm x 500 mm (2 µm particle size) C18 EASY-Spray column at 250 nL/min (Thermo Scientific), coupled to an Orbitrap Fusion Lumos mass spectrometer. Peptides were separated using a 60-minute linear gradient from 2-35 % buffer B (Buffer A: 5 % DMSO, 0.1 % formic acid in water. Buffer B: 5 % DMSO, 0.1 % formic acid in acetonitrile). The samples were analyzed on the mass spectrometer in Data-Dependent Acquisition mode. MS1 scans were acquired in the Orbitrap with an m/z range of 400 – 1500 m/z at a resolution of 120,000 and an AGC target of 4×10^5. Precursors between charge states 2+ and 7+ were selected for HCD fragmentation using the Advanced Precursor Determination option with an intensity threshold of 2.5×10^4. Selected precursors were isolated using the quadrupole with a 1.6 m/z isolation window and fragmented using HCD with a normalized collision energy of 30%. MS2 spectra were acquired in the Orbitrap using a resolution of 30,000, a maximum injection time of 54 ms and an AGC target of 5×10^4.

LC-MS/MS Analysis of Individual Biological Samples

The individual samples were analyzed on the same nanoLC-MS/MS system as above. A

45-minute linear gradient was used from 2-35 % buffer B with the same buffer composition as

above. In contrast to the pool samples, the individual samples were analyzed using the SWATH

DIA method [16]. The sample analysis order was randomized, and analyses of aliquots of the

pooled sample used for library generation were scheduled every 20 runs throughout the sequence

as a quality control. MS1 scans were acquired in the Orbitrap with an m/z range of 350 – 1650

m/z at a resolution of 120,000, an AGC target of 4 x 105 and a 3 second cycle time. MS2 scans

were then acquired in stepped isolation windows with a 1 Th overlap between each window; first

from 350-380 m/z up to 930-960 m/z in increments of 30 Th (i.e. 21 scans with midpoints of

365, 394 … 916, 945), followed by a 100 Th window scan of 959-1059 m/z and a 592 Th scan of

1058-1650 m/z.

Fragmentation of these windows was performed using a normalized collision energy of 25 %

with a stepped collision energy of 10 %. MS2 spectra were acquired in the Orbitrap using a

resolution of 30,000, a maximum injection time of 54 ms, an AGC target of 5 x 104 and a scan

range of 360-1650 m/z.

Western Blot Validation

Samples were compared as 5 Upper Tertile (UT) versus 5 Lower Tertile (LT)within a

single age category (younger; total n=20, or older; total n=20) on each gel. Kidney homogenates

at 1µg/µL of protein were denatured at 90☐C in Laemmli buffer and separated using 4-12% pre-

cast Bis-Tris gels (Thermo Fisher Scientific, Massachusetts, USA) in the case of VTN and

APOE western blots and 16% pre-cast Tricine gels (Thermo Fisher Scientific, Massachusetts,

USA) in the case of PREB and CST3 western blots, in both cases using MOPS running buffer

and followed by transfer onto a PVDF membrane (Thermo Fisher Scientific, Massachusetts,

USA). Membranes were then blocked in Intercept (TBS) Blocking Buffer (LiCOR P/N 927-

60001) and incubated with primary antibodies overnight at 4□C. Antibodies used were rabbit

polyclonal anti-PREB (Thermo Fisher Scientific PA5-53125), mouse polyclonal anti-Vitronectin

(R&D, MAB2349), rabbit monoclonal anti-APOE (16H22L18) (Thermo Fisher Scientific,

701241), rabbit monoclonal anti-CST3 (D6U3E) (Cell Signaling Technology, 24840) and

mouse monoclonal anti-β-actin (Sigma, A5316) for protein normalization. The membranes were

then incubated in species appropriate secondary antibodies (RDye® 800CW Goat anti-Mouse

IgG Secondary Antibody and IRDye® 680RD Goat Anti-Rabbit IgG Secondary Antibody,

LiCOR, USA). Finally, blots were imaged using the LI-COR Odyssey system (LiCOR,

Nebraska, USA). Analysis and quantification were performed using LiCOR Image Studio

(Version 2.2). Protein expression was normalized against β-actin and the fold change was

calculated relative to the per-gel mean value of the Upper Tertile group. For each protein, fold

changes relative to UT were combined across all gels within each age category, log2

transformed, and the difference between UT and LT calculated by t-testing without assumption

of equal variance.

Statistical Analyses

Proteomic Data Processing

Both the DDA fractionated pools and all SWATH samples and pool data were analyzed

simultaneously using DIA-NN v1.7.12 [20]. MS/MS spectra from the DDA pools were searched

against UniProt Reference *Homo sapiens* database (retrieved 15/10/2020) with default settings,

including 1 missed cleavage, oxidation of methionine as a variable modification and

carbamidomethylation of cysteine as a fixed modification, to generate a spectral library. This

was then cross referenced against the SWATH data to quantify peptides, and thus proteins,

within each SWATH sample and pool run. Precursor FDR was set to 1%.

Subsequent analysis of the DIA-NN output and integration with the clinical data was

performed in R v4.0.2. One sample had extremely low average intensity and more than 15%

missing values, so was eliminated from the analysis. Across the remaining 185 samples and

pools, proteins with more than 50% missing values were eliminated. Intensity values were

transformed by VSN (R package 'vsn' [21]), and the remaining missing values were imputed by a

k-nearest neighbor approach (R package 'impute' [22]).

Clinical Variable Preprocessing

Clinical variables were subdivided into Donation after Brain Death (DBD)-specific

variables, Donation after Cardiac Death (DCD)-specific variables and jointly applicable

variables (see annotation, Supplementary Table 1). DBD- and DCD-specific variables were

considered for the purposes of assessing correlation with outcome but were not considered for

statistical analyses applied to the full dataset.

For significance testing of outcome differences between donor and recipient

characteristics, and for all modelling, eGFR values for both donor measurements and recipient

measurements at 12-month post-transplantation were stratified into tertiles - Lower Tertile (UT;

eGFR < 40), Intermediate Tertile (IT; $40 \leq$ eGFR < 60) and Upper Tertile (UT; eGFR $\geq$ 60)

based on their distribution. Missing values in the continuous and tertile-stratified forms of the

variables were imputed for each sample by finding the 'set of neighbors' by 3-month eGFR, i.e.

the 10 samples with the closest recipient eGFR at 3 months posttransplant, then taking the mean

eGFR12 (ignoring any missing values) within that set of neighbors.

We curated the non-DBD/DCD specific clinical variables to remove those inappropriate

for modelling (single-instance categories, variables which duplicated another variable in

different units); the final list is given in Supplementary Table 2. HLA mismatches were modelled

as 'Match Grade' with levels None; no mismatches, Favorable; no DR and one or fewer B

mismatches, and Non-Favorable; at least one DR or two B mismatches (Supplementary Figure

S2 and Supplementary Table ST1).

For curated clinical variables, missing values were imputed for each sample in a similar

manner. A set of neighbors was built by finding the 10 samples with the smallest Gower's

distance across all variables (multiple data types). We then took a relevant summary statistic of

the non-missing values within the set of neighbors for each imputed value. For numeric values,

the mean was taken. For categorical values, the most frequent category across the whole dataset

was taken, breaking ties by iteratively shrinking the set of neighbors by removing the most

distant from the sample to be imputed, until there was a single most frequent category.

Outcome Subgroup Comparison

Differences between outcome subgroups within DBD and DCD donor types (separately)

were tested using Fisher's exact test for categorical variables and t-tests for numeric variables as

appropriate.

Clinical variable association was calculated depending on the type of each variable in

pairwise comparisons. Numeric-numeric comparisons were by Pearson's r. Numeric-categorical

comparisons were by the square root of the proportion of variance explained (eta) from an

ANOVA model where the numeric variable was taken as the response. Categorical-categorical

comparisons were by Cramér's V. Hierarchical clustering was performed using the single-linkage

method to avoid composition of comparison types.

The proteomic and clinical data were matched in R by sample identifier. Based on an

initial scree plot of the variance distribution, unsupervised clustering of the proteomic data was

performed by k-means clustering with k=4. The number of initial random centroids and the

maximum number of iterations were both set to 10.

Training and Test Data Split

We split our data into a training and test sets, sampling equally across stratified eGFR. Of

the 185 samples, 2/3 were used for training ('training set', 118 kidneys), and 1/3 were used for

testing ('test set', 61 kidneys). Six paired kidneys (3 pairs) were reserved from both sets and used

to assess MS and model performance ('QC set', 6 kidneys).

Machine Learning Feature Selection

Using sample assigned to the training dataset, we modelled the combined dataset of all

protein abundance data plus the curated donor clinical variables (Supplementary Table S2)

against ranked 12 month posttransplant eGFR, using Prediction Rule Ensemble (PRE) modelling

(R package 'pre'[23]). We used the 'gpe' function allowing linear fits, decision tree fits and

multivariate adaptive regression spline fits (via R package 'earth' [24]) to be considered for each

ensemble. Decision tree learning was set to be 'random forest'-like, with 500 initial trees

generated and boosting disabled to allow parallel processing. Other settings (including tree

pruning and the parameters for linear and spline fits) were left as default; tree depth was

therefore limited to the default 3 decision levels. Ensemble modelling was performed in an

iterative manner. At each stage, modelling was performed on the set of predictors that excluded

proteins listed in the final ensemble of all previous models. Clinical variables were never

excluded. Modelling was repeated for 2000 iterations and all proteins appearing in any rule

ensemble, or with high correlation (Pearson's r>0.65) to any of these candidates, were selected

for further analysis.

Regression Modelling

Based on the outcome of feature selection, we used regularized regression (relaxed

LASSO, package 'glmnet', using the cv.glmnet function with 20-fold cross validation, selecting

as the final model the model that maximized the shrinkage parameter lambda such that it was

within 1 standard error of the lambda value that had the smallest cross-validation error, i.e. the

'lambda.1se' model) to regress each protein, donor age and protein:age terms against linearized

outcome, defined as the proportion of eGFR12 values in the NHS Blood and Transplant National

Registry between 2016 and 2021 inclusive (6 years) that were less than the observed eGFR12

(i.e. a normalization to population distribution quantile). An independent age-only model was

also fit against the training dataset using the same parameters. For each protein model and the

age-only model we calculated the prediction root-mean-square error (RMSE). Proteins with a

higher RMSE than the independent donor age model, or whose model did not retain either the

protein or protein:age term were discarded.

Functional Network Analysis

The final list of proteins resulting from regression modelling was queried using the

Enrichr platform (R package 'enrichR'[25]) against the Reactome 2022 database. Annotation term

assignments were filtered at 5% FDR. From the set of candidates with at least one assigned term

across all three databases, a connection graph was generated (R package 'igraph'[26]) with nodes

representing proteins and edges representing shared annotation terms. Nodes (proteins) were

clustered using the walktrap community detection algorithm[27] as implemented in igraph. Within-

community enrichment for annotation terms was calculated by Fisher's exact test.

Age-Protein-Outcome Clustering

For each protein, eGFR12 was predicted using the corresponding relaxed LASSO model

for donor ages 20,21,22…80 and protein quantiles 0,0.01,0.02…1, resulting in a 61x101 matrix.

Matrix-matrix distances were computed using the Frobenius distance (R package

'StatPerMeCo'[28]), and proteins were clustered according to these pairwise distances by

hierarchical clustering.

Spatial Correlation Analysis

Processed, normalized AKI and CKD spatial scRNA-seq expression data generated by

Lake *et al.*[29] were obtained from CELLxGENE

(https://cellxgene.cziscience.com/collections/bcb61471- 2a44-4d00-a0af-ff085512674c).

Proteins identified by feature selection and LASSO regression filtering were matched to the

expression dataset by the 'Genes' column in the DIA-NN output. AKI:CKD correlation in

matched versus unmatched genes in each characterized spatial location was compared using the

approach described by Fisher[30] (R package 'cocor'[31]).

RESULTS

Selected Samples were Demographically Balanced Across Outcome Strata

Samples were selected to provide a balanced representation of the UK donor population

(Table 1) and reproduced generally observed trends in terms of the correlation between eGFR12

and clinical variables; we found the strongest associations were donor age (Pearson's r=-0.52),

and recipient age (r=-0.28) (Supplementary Figure S1).

For an interpretable analysis of key clinical factors, we considered our samples by

eGFR12 stratum Lower Tertile (LT; eGFR12 < 40), Intermediate Tertile (IT; 40≤eGFR12<60),

and Upper Tertile (UT; eGFR12≥60) all units ml/min/1.73 m^2 (Figure 1). We investigated

associations between clinical variables and stratified eGFR12 subgroups within each donor type,

and between donor types within stratified eGFR12 subgroups (Supplementary Table ST1); the

only variables with significant difference between outcome groups across donor types were the

UK Kidney Donor Risk Index; UKKDRI[8] (ANOVA F-test; DBD: p=1.298e-6; DCD: p=3.946e-

7), donor age (ANOVA F-test; DBD: p=1.253e-9; DCD: p=1.196e-7), histories of hypertension

(ANOVA F-test; DBD: p=0.0020; DCD: p=0.1069). Histories of diabetes (ANOVA F-test;

p=0.6188; DCD: p=0.2348) and terminal serum creatinine levels (ANOVA F-test; DBD:

p=0.6972; DCD: p=0.6448) were similar across outcome subgroups although the latter was

higher in DBD than in DCD in the UT group (t-test; p=0.0443).

Integration of Kidney Proteomes with Clinical Metadata by Rule Ensemble and Regression

Modelling Identifies Outcome-Associated Proteins

Proteomic analysis quantified 2984 protein groups with 50% or less missing values (out

of 7790 identified protein groups in total) over 185 samples and 20 interspersed sample pools

(Supplementary Figure S2A). Analysis of sample pools showed minimal sample acquisition-

related variance (squared mean pairwise Z-corrected Pearson's r=0.94). The 3 pairs of kidneys

showed high correlation of protein intensity values between donor pairs (Pearson's r=0.71, 0.92

and 0.91; Supplementary Figure S2B).

We initially explored the proteomic data using Principal Component Analysis (PCA) to

find underlying linear trends. Sample variance concentrated in the first two principal components

(PC1: 20.01%; PC2: 13.38%; Figure S3). K-means clustering identified 4 distinct clusters

(Figure S3; Figure S4A) which associated with donor type, with a preponderance of DBD

samples towards Cluster 2 and a preponderance of DCD samples towards Cluster 4 (Figure S4B,

upper left panel; p=0.0235), but did not associate strongly with recipient eGFR (p=0.4134),

donor eGFR (p=0.1684), or donor age (p=0.7907) (Figure S4B, upper middle, upper right and

lower left panels). There was a weakly significant association between cluster membership and

donor BMI (p=0.0350) and with donor serum creatinine (p=0.0326) (Figure S4B, lower middle

and lower right panels).

To assess individual protein relationships with outcome, we adopted a descriptive

modelling approach, using a subset of our data ('training set'; 2/3 of data) to find protein models

which predicted eGFR12 better than donor clinical data alone, then assessing model performance

against unseen (i.e. held out) test data ('test set', 1/3 of data). Six of the kidneys analyzed (3

pairs) were pairs from the same donor; these were reserved from both training and test data for

quality control ('QC set', 6 kidneys). To create our train/test split, we randomly selected equal

numbers of samples for the training set within each of the eGFR12 strata described above, to

sample equally across outcome range.

To identify possible outcome-associated proteins, relevant clinical variables and potential

protein-clinical variable interactions, we used iterative Prediction Rule Ensembles[23] (PRE)

learning on our training set to select features among the set of quantified proteins and donor

type-independent donor clinical variables. Briefly, PRE identifies a minimal ensemble of

explanatory rule (functions of variables) for a given response (here, ranked eGFR12) allowing

for nonlinear associations and variable interactions. To build a catalog (rather than minimal set)

of explanatory proteins, we repeated our analysis 2000 times, removing proteins identified in the

rule ensemble at each iteration from the dataset for future iterations, retaining clinical variables.

This process generated 195 candidate proteins; we further supplemented this list with proteins

that had high correlation (Pearson's r>0.65) with any of those candidates; bringing the final list

up to 255 candidates.

The only donor clinical variable term to feature consistently in rule ensembles was donor

age, appearing in all 2000 ensembles generated. We individually tested each protein candidate

for association with outcome, including protein, donor age, and age:protein interaction terms

using LASSO regression[32] to aim for the simplest explanatory models (i.e. that include only the

minimum necessary terms). To ensure models would generalize beyond our data, for the final

modelling we linearized the eGFR12 measurement against UK NHS Blood and Transplant

National Registry data. We discarded candidates whose model discarded both the protein and

age:protein terms, or had a higher root-mean-square error (RMSE) of prediction than a model

built with donor age alone.

After filtering we had identified 144 proteins which associated with outcome

(Supplementary Table 2). The mean RMSE of our protein models was 25.76 ml/min/1.73m^2 in

our training data, and fell slightly to 22.25 ml/min/1.73m^2 in our test data, indicating the models

were not over-fit (Supplementary Figure S5).

Functional Analysis of Outcome-Associated Proteins Reveals Immuno-Metabolic Pathway

Clusters

We performed a network analysis of shared Reactome pathways (Figure 2A). Walktrap

clustering revealed 4 major clusters of shared-pathway proteins (Table 2); Immune Regulation &

Complement Activation, Metabolism, Protein Metabolism & Modification, and Cell Cycle. To

validate our findings, we selected three representative proteins with available antibodies and

known biological relevance (Vitronectin (VTN); fibrosis, Apolipoprotein E (APOE); CKD risk,

Cystatin C (CST3); nephron function) and confirmed that all three showed differences between

low and high eGFR outcome sample subgroups by western blot (Figure 2B). Furthermore, all

three proteins consistently predicted similar outcomes for each pair of kidneys within the triple-

pair QC set, and correctly separated the two below-median outcome (eGFR12<50) pairs from the

above-median outcome (eGFR12>50) pair (Figure S6).

Association of Proteins with Posttransplant Outcome is Modulated by Donor Age

For all 144 proteins, the minimal model retained an age:protein interaction term where

the predictive effect of protein abundance was modulated by age, independent of the effect of

age alone or protein abundance alone (Supplementary Table 2). To visualize these effects, we

used each model to predict eGFR12 across increasing donor age and protein quantile. The

interplay between protein quantile and age could be broadly grouped (by hierarchical clustering)

into 3 clusters with protein to eGFR12 associations that showed different patterns across donor

age (Figure 3), with about a third (31%) of candidates, including CST3, falling into a cluster with

a profound effect of age on protein to eGFR12 association at high donor age.

Comparison to Spatial scRNA-Seq Data Reveals Localization of Outcome-Associated

Signal

As an independent validation of our findings, we sought to contextualize them in the

wider context of kidney damage. To do this, we compared the expression levels of our candidate

protein set to a recent spatial scRNA-seq dataset comparing AKI and CKD[29]. This initial

comparison revealed that all 144 of our candidates were matched to transcripts reported in this

external dataset, and, consistent with our proteomic data. Two of our highlighted candidates

associated with outcomes, APOE and CST3, were also highlighted as associated with fibrosis

and inflammation damaged tubules in this dataset.

We then investigated how the expression levels of transcripts corresponding to our set of

144 proteins changed between AKI and CKD. We reasoned that protein and gene expression

data that carries outcome-predictive information must reflect differences in organ injury.

Therefore, between different injurious scenarios, we would expect gene expression that is

predictive (i.e. discriminatory) to have lower correlation than genes whose expression change

was linked to general inflammation and stress response. We compared the AKI:CKD expression

correlation of our set of candidates versus the expression correlation of all other transcripts in the

dataset. Since the dataset is spatially resolved, we were able to make this comparison across

regions of the nephron. We observed that our candidate protein set had stronger discriminatory

power (i.e. significantly lower correlation; Fisher test, $p=4.04e\text{-}11$) than background in distal

convoluted tubule epithelial cells and in surrounding structures, but not in leukocytes or in

globally aggregated data (Figure 4).

This result gave us confidence that the 144-candidate set we report represents signatures

of specific organ injury, and suggests that proteomic signals in distal convoluted tubule may be

particularly representative of the extent to which injury impacts future functionality.

DISCUSSION

This study presents the first large unbiased human kidney tissue proteomics dataset for

deceased donor kidneys. We examined the relationship between posttransplant kidney function

with pretransplant kidney proteomes by analyzing 185 deceased donor kidneys with complete

donor and recipient associated metadata. Although our study was not aiming to report a single

biomarker, our large cohort, our unique machine learning approach, and finally alignment of

proteomic data with a large spatial single cell transcriptomics dataset on healthy and diseased

kidney substantiates our key findings. We describe an integration of kidney proteome with

clinical metadata and show that modelling age modulation of proteomic signals provides

enhanced resolution of donor kidney quality stratification and highlights biological mechanisms.

Our analysis reveals the importance of integrating across both subclinical and clinical

data. Exploring our data using iterative PRE feature selection, a substantial number of proteins

were revealed to be relevant, but only one clinical variable, donor age. Donor age is a key

contributor in clinical decisions and is a strongly weighted term in extant kidney allocation

scoring systems [8,33], but in the case of all reported candidate proteins, prediction models retained

a protein:donor age interaction term. This second-order effect has not (to our knowledge) been

explored in transplantation, and may be important to fully understanding molecular predictors.

A clinical variable notable by its omission from our association findings was donor

type[34]. It is possible that outcome-predictive information 'carried' by donor type is also derivable

from the proteome (proteomic data were able to partially distinguish samples based on type even

when considering only variance across linear combinations of proteins; Figure S4). Without

disputing donor type-specific mechanisms of kidney damage[35], our data are consistent with the

idea that location and type of damage may be a greater contributor towards recovery potential[36]

than mechanism of injury.

Kidney metabolism is altered as a result of biological stress occurring during donor

management, in both DBDs and DCDs[37]. Within our final list of 144 proteins associated with

outcome there is a common theme of implication in immune response to kidney injury (including

both chronic injury, and acute injury) as a result of metabolic disruption, particularly responses

associated with ischemia. We highlighted three proteins from our set of 144 outcome-associated

candidates as a sanity check; all three are examples of known chronic damage indicators that we

find here to have a donor organ pre-transplant predictive association.

Vitronectin (VTN) is a primary component of the extracellular matrix involved in cell

adhesion, enhancing the activity of plasminogen activator inhibitor-1 and inhibition of the

terminal complement pathway[38], and is a potential fibrotic biomarker[39].

Apolipoprotein E (APOE) stands out as having previously reported genetic allele age-

related associations with disease and organ dysfunction including risk of Alzheimer's Disease[40]

(with the strongest effect manifesting around age 65[41]), macular dysfunction, atherosclerosis and

pulmonary scarring[42,43], and evidence for shared allele risk across diseases[44]. In kidneys, APOE

plays an important role in lipid metabolism to regulate the growth and survival of mesangial cells

and preserve organ function[45]; it is a marker for outcome in transplant recipients[46–48], and there is

evidence for *APOE* genotype association with kidney dysfunction risk[49–51], possibly manifested

by lipidomic differences between allelic profiles[52]. We have previously reported small (not

statistically significant) increases in APOE due to ischemic reperfusion injuries[53] possibly

explained by a role in senescence mediation[54]. There is existing evidence for similar allele

dependent transplant outcome effects in another apolipoprotein (APOL1)[55], suggesting that both

APOE genotype and the broader apolipoprotein allelic profile may play an important role in

posttransplant graft function.

Cystatin C (CST3) is particularly noteworthy as, measured in serum, it is a known and

effective general biomarker for kidney function and has predictive power for outcomes in

transplant recipients[56–58]. Our evidence indicates a further association between CST3 levels in

donor kidney tissue and outcome; moreover, that this effect is age dependent, starting around age

40. Serum CST3 is relatively independent of age in children and young adults[59], but may also

show age association in later years[60].

A potential hurdle in contextualizing our findings in existing orthogonal transcriptomic

data was that proteomes and transcriptomes are generally poorly correlated in terms of

abundance changes[61]. In order to avoid this problem, we considered how the pattern of injury

scenario-related differences changed between predictive and background signals within the same

transcriptomic dataset[29]. The spatial component of this dataset further allowed us to show that

injury-specific signals within our 144-protein set localized most strongly to the distal convoluted

tubule (DCT) epithelium. Damage to DCT epithelial cells can be predictive of outcome[62]; the

interplay of proximal and distal injury is complex[63], but previous work has suggested that DCT

epithelial cells can play an important protective and damage repair role across the nephron,

expressing survival and reparative factors in response to injury[64]. Indications that aging is

associated with accumulation of senescent epithelial cells with a maladaptive stress response[29]

suggest a mechanism whereby aging related senescent cell accumulation could reduce the ability

of DCT epithelia cells to protect and promote recovery of injury sustained by the proximal

tubules. This would be consistent with our findings (immuno-metabolic and ischemia response

functional association, and spatially localized response) and the negative donor age correlation

with transplant outcome, and might explain recent successes with senescence inhibitors in

treating CKD[65], suggesting that routes to stimulate or enhance the DCT regenerative effect could

be avenues for organ preservation.

Our list of outcome-associated candidates cannot be exhaustive. Practicalities of sample

acquisition limited sampling of a wide range of outcomes outside the 30-60 donor age range,

especially limited Upper Tertile outcome events in older donors. Organ allocation algorithms

impose a close link between donor and recipient age in the sample cohort, so while we interpret

these age-moderated effects in terms of organ resilience in older donors, it could also represent a

greater ability to repair a given level of damage in younger recipients. Further, we consider only

chronological donor age, rather than a more nuanced representation of the epigenomic biological

clock [66], which may to account for some variation observed with respect to both donors and

recipients.

It is immediately clear from our results that the strength of the donor age factor is

enormous relative to any other protein or clinical effect; this age effect is liable to dominate any

prediction weighting and reduce the accuracy of estimated protein contribution. A much larger

cohort could mitigate this issue, especially if paired with variant sequencing to understand

genetic diversity. Advances in high-throughput proteomics techniques continue to increase

feasible cohort sizes[67] but fundamental limitations on organ acquisition remain. Archiving at

scale of clinical samples in bioresources such as the QUOD biobank to parallel advancements in

big data analysis and interpretation platforms is therefore necessary for future development of

granular evidence-based decision making.

However, given the limitations of our dataset, our protein models generalized well to

samples unseen during model training (Figure S5), and showed promise for outcome-

classification prediction (Figure S6) suggesting that, with a larger training cohort to address the

caveats acknowledged above, a substantial component of early posttransplant outcome may be

predictable solely using subclinical measurements moderated by donor age. The biological

themes of the 144 proteins identified herein reinforce known immuno-metabolic mechanisms of

kidney injury but raise interesting possibilities for further work, especially with regard to donor

genetic background, and also suggest that the possibility of donor age-moderated weighting

should be considered as a matter of course in future work.

 SUPPLEMENTARY MATERIALS

Supplementary Table ST1: Clinical variable p-values for association with donor type and

outcome.

Supplementary Table ST2: Summary of results for all candidate proteins.

Note that coefficient values provided are for linearized eGFR12, i.e. they relate to

eGFR12 quantile ranging from 0 to 1.

Supplementary Figure S1: Donor and recipient clinical and demographic data association with

recipient 12-month eGFR rank.

Single-linkage hierarchical clustering of curated, imputed clinical variables by relative

association strength (taking distance as 1-association). The outcome variable (ranked

recipient eGFR at 12 months post-transplantation) is highlighted in red.

Supplementary Figure S2: Protein quantification quality.

A: Missingness comparison: Proteins are shown ranked by the number of missing values

across all samples and the twenty standard pools, excluding one run which was removed

due to low signal. 2984 proteins had missing values in 50% or less runs.

B: Paired Kidney Comparison: Protein abundance values from paired kidneys (left/right)

from 3 individual donors were compared, as these are effectively biological replicates. x

axes: value in left kidney. y axes: value in right kidney. Inset: Pearson's r correlation

coefficient.

Supplementary Figure S3: Scree plot of variance represented by the first ten principle

components in the proteomic data.

A reasonable number for the cluster parameter (k) supplied for k-means clustering (see

Figure S4) lay between 3 and 5 based on the 'elbow' method'; we selected k=4.

Supplementary Figure S4: Unbiased analysis of pretransplant kidney proteomes and cluster

associations.

A: Unbiased analysis of proteomic data by k-means clustering. Sample separation by

Principal Component Analysis. Top Left: Samples were assigned to four clusters by k-

means. Bottom & Right: There was a difference in the distribution of DBD and DCD

donors across clusters, with the DBD donors being more heavily concentrated in Cluster

2 ('+' symbol; orange shading), and DCD in Cluster 4 ('x' symbol; pink shading)

B: There were no associations between proteome clusters and most donor and recipient

factors, except for mildly significant differences in donor BMI and creatinine (selected

comparisons shown; left-right, top-bottom: donor type, recipient 12-month posttransplant

eGFR (outcome), donor eGFR, donor age, donor BMI, donor creatinine at retrieval).

Supplementary Figure S5: Performance of individual protein with age models on unseen data.

For each protein, the protein term plus age term and protein:age interaction term were

modelled against linearized 12-month posttransplant eGFR (eGFR12) using LASSO. For

proteins passing filtering, with eGFR root-mean-square error (RMSE) better than an age-

only model, we compared the RMSE achieved on the model training data against the

RMSE achieved on held-out test data. We observed that the models actually achieved

slightly better performance on the test data, reassuring us that no model was over-fit to

the training data (i.e. all models generalized well to unseen data).

Supplementary Figure S6: Performance of VTN, APOE and CST3 models on paired kidney data.

Six of the analyzed kidneys were paired (i.e. two came from each of three donors). These

data were not used for training or testing but reserved for QC of the proteomics (Figure

S2). Although our analysis was focused on identification of outcome-associated protein

signals rather than prediction of eGFR12 (due to cohort size limitations, we do not claim

to have a maximally biologically representative training set), we nevertheless used these

paired kidneys to assess the consistency of our modelling in predicting above/below

median outcomes in the three proteins we highlighted as particularly interesting. In all

three pair cases the outcomes in (different) recipients were similar within each pair, and

for all three proteins the model consistently predicted the correct above/below median

classification for all six kidneys.

DATA AND MATERIALS AVAILABILITY

603 The mass spectrometry proteomics data have been deposited to the ProteomeXchange

604 Consortium via the PRIDE [68] partner repository with the dataset identifier PXD033428.

DISCLOSURE AND FUNDING

This study was supported by NHS Blood and Transplant funding awarded to MK & RJP. SF was

supported by Kidney Research UK, grant reference KS_RP_002_20210111 awarded to MK.

PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to

BMK. Authors declare that they have no competing interests.

Author contributions:

Conceptualization: MK

Methodology: PDC, SF, RV, SD, RF, BMK, AS, ES, RJP, MK

Investigation: PDC, SF, RV, PJ, SD, IV, KT, AS

Visualization: PDC

616    Funding acquisition: BMK, RJP, MK

617    Project oversight: MK

618    Supervision: RF, AS, MK

619    Writing – original draft: PDC, ES, MK

620    Writing – review & editing: All authors

REFERENCES

1. Callaghan CJ, Mumford L, Pankhurst L, Baker RJ, Bradley JA, Watson CJE. Early Outcomes of the New UK Deceased Donor Kidney Fast-Track Offering Scheme. *Transplantation*. 2017;101(12):2888-2897. doi:10.1097/TP.0000000000001860

2. Summers DM, Johnson RJ, Hudson AJ, et al. Standardized deceased donor kidney donation rates in the UK reveal marked regional variation and highlight the potential for increasing kidney donation: a prospective cohort study†. *Br J Anaesth*. 2014;113(1):83-90. doi:10.1093/bja/aet473

3. Denic A, Glassock RJ, Rule AD. The Kidney in Normal Aging: A Comparison with Chronic Kidney Disease. *Clin J Am Soc Nephrol*. 2022;17(1):137-139. doi:10.2215/CJN.10580821

4. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. *J Am Soc Nephrol*. 2007;18(10):2758-2765. doi:10.1681/ASN.2007040422

5. Ishani A, Xue JL, Himmelfarb J, et al. Acute Kidney Injury Increases Risk of ESRD among Elderly. *J Am Soc Nephrol*. 2009;20(1):223-228. doi:10.1681/ASN.2007080837

6. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of donor age and cold storage time on outcome in recipients of kidneys donated after circulatory death in the UK: a cohort study. *Lancet*. 2013;381(9868):727-734. doi:10.1016/S0140-6736(12)61685-7

7. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. *Transplantation*. 2009;88(2):231-236. doi:10.1097/TP.0b013e3181ac620b

8. Watson CJE, Johnson RJ, Birch R, Collett D, Bradley JA. A Simplified Donor Risk Index for Predicting Outcome After Deceased Donor Kidney Transplantation. *Transplantation*. 2012;93(3):314-318. doi:10.1097/TP.0b013e31823f14d4

9. Neuberger J, Callaghan C. Organ utilization - the next hurdle in transplantation? *Transpl Int*. 2020;33(12):1597-1609. doi:10.1111/tri.13744

10. Clayton PA, Dansie K, Sypek MP, et al. External validation of the US and UK kidney donor
risk indices for deceased donor kidney transplant survival in the Australian and New Zealand
population. *Nephrol Dial Transplant*. 2019;34(12):2127-2131. doi:10.1093/NDT/GFZ090

11. Yu K, Husain SA, King K, Stevens JS, Parikh CR, Mohan S. Kidney nonprocurement in
deceased donors with acute kidney injury. *Clin Transplant*. Published online August 4,
2022:e14788. doi:10.1111/ctr.14788

12. Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated
with kidney allograft failure. *Kidney Int*. 2019;95(1):199-209.
doi:10.1016/j.kint.2018.08.047

13. Liu C, Hall IE, Mansour S, Thiessen Philbrook HR, Jia Y, Parikh CR. Association of
Deceased Donor Acute Kidney Injury With Recipient Graft Survival. *JAMA Network Open*.
2020;3(1):e1918634. doi:10.1001/jamanetworkopen.2019.18634

14. Mansour SG, Khoury N, Kodali R, et al. Clinically adjudicated deceased donor acute kidney
injury and graft outcomes. *PLoS One*. 2022;17(3):e0264329.
doi:10.1371/journal.pone.0264329

15. von Moos S, Akalin E, Mas V, Mueller TF. Assessment of Organ Quality in Kidney
Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet.
Front Immunol. 2020;11:833. doi:10.3389/fimmu.2020.00833

16. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated
by data-independent acquisition: a new concept for consistent and accurate proteome
analysis. *Mol Cell Proteomics*. 2012;11(6):O111.016717. doi:10.1074/mcp.O111.016717

17. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma
proteomics. *Mol Syst Biol*. 2017;13(9):942. doi:10.15252/msb.20156297

18. Connor KL, O'Sullivan ED, Marson LP, Wigmore SJ, Harrison EM. The Future Role of
Machine Learning in Clinical Transplantation. *Transplantation*. 2021;105(4):723-735.
doi:10.1097/TP.0000000000003424

19. Raynaud M, Aubert O, Divard G, et al. Dynamic prediction of renal survival among deeply
phenotyped kidney transplant recipients using artificial intelligence: an observational,
international, multicohort study. *The Lancet Digital Health*. 2021;3(12):e795-e805.
doi:10.1016/S2589-7500(21)00209-0

20. Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks
and interference correction enable deep proteome coverage in high throughput. *Nat Methods*.
2020;17(1):41-44. doi:10.1038/s41592-019-0638-x

21. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization
applied to microarray data calibration and to the quantification of differential expression.
Bioinformatics. 2002;18(Suppl 1):S96-S104. doi:10.1093/bioinformatics/18.suppl_1.S96

22. Hastie T, Tibshirani R, Narasimhan B, Chu G. *Impute: Imputation for Microarray Data*.;
2021. http://www.bioconductor.org/packages/release/bioc/html/impute.html

23. Fokkema M. Fitting prediction rule ensembles with R package pre. *J Stat Softw*. 2020;92(1):1-30. doi:10.18637/jss.v092.i12

24. Milborrow. Derived from mda:mars by T. Hastie and R. Tibshirani. S. *Earth: Multivariate Adaptive Regression Splines*.; 2011. http://CRAN.R-project.org/package=earth

25. Jawaid W. *EnrichR: Provides an R Interface to "Enrichr."*; 2021. https://cran.r-project.org/package=enrichR

26. Csárdi G, Nepusz T. The igraph software package for complex network research. *InterJournal*. 2006;Complex Systems:1695.

27. Pons P, Latapy M. *Computing Communities in Large Networks Using Random Walks*. (Yolum P, Güngör T, Gürgen F, Özturan C, eds.). Springer; 2005. doi:10.1007/11569596_31

28. Trucios C. *StatPerMeCo: Statistical Performance Measures to Evaluate Covariance Matrix Estimates*.; 2017. https://CRAN.R-project.org/package=StatPerMeCo

29. Lake BB, Menon R, Winfree S, et al. An atlas of healthy and injured cell states and niches in the human kidney. *Nature*. 2023;619(7970):585-594. doi:10.1038/s41586-023-05769-3

30. Fisher RA. *Statistical Methods for Research Workers*. Oliver and Boyd; 1925. https://openlibrary.org/books/OL17638383M.opds

31. Diedenhofen B, Musch J. cocor: A Comprehensive Solution for the Statistical Comparison of Correlations. *PLoS ONE*. 2015;10(4):e0121945. doi:10.1371/journal.pone.0121945

32. Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. *J Stat Softw*. 2010;33:1-22. doi:10.18637/jss.v033.i01

33. Li B, Cairns JA, Robb ML, et al. Predicting patient survival after deceased donor kidney transplantation using flexible parametric modelling. *BMC Nephrol*. 2016;17(1):51. doi:10.1186/s12882-016-0264-0

34. Gill J, Rose C, Lesage J, Joffres Y, Gill J, O'Connor K. Use and Outcomes of Kidneys from Donation after Circulatory Death Donors in the United States. *J Am Soc Nephrol*. 2017;28(12):3647-3657. doi:10.1681/asn.2017030238

35. Vaughan RH, Kresse JC, Farmer LK, et al. Cytoskeletal protein degradation in brain death donor kidneys associates with adverse post-transplant outcomes. *Am J Transplant*. Published online December 8, 2021. doi:10.1111/ajt.16912

36. Kosmoliaptsis V, Salji M, Bardsley V, et al. Baseline donor chronic renal injury confers the same transplant survival disadvantage for DCD and DBD kidneys. *Am J Transplant*. 2015;15(3):754-763. doi:10.1111/ajt.13009

37. Damman J, Bloks VW, Daha MR, et al. Hypoxia and Complement-and-Coagulation Pathways in the Deceased Organ Donor as the Major Target for Intervention to Improve Renal Allograft Outcome. *Transplantation*. 2015;99(6):1293-1300. doi:10.1097/TP.0000000000000500

38. De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin. *EMBO Rep*. 2016;17(7):982-998. doi:10.15252/embr.201541681

39. Carreras-Planella L, Cucchiari D, Cañas L, et al. Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts. *J Nephrol*. 2021;34(3):861-874. doi:10.1007/s40620-020-00886-y

40. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. *Nat Rev Neurol*. 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263

41. Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. *PLoS Med*. 2020;17(8):e1003289. doi:10.1371/journal.pmed.1003289

42. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev Genomics Hum Genet*. 2000;1:507-537. doi:10.1146/annurev.genom.1.1.507

43. Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung Disease. *Am J Respir Cell Mol Biol*. 2016;55(2):159-169. doi:10.1165/rcmb.2016-0060TR

44. Miwa K, Tanaka M, Okazaki S, et al. Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. *Neurology*. 2014;82(12):1051-1057. doi:10.1212/WNL.0000000000000251

45. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A Protective Role for Kidney Apolipoprotein E: REGULATION OF MESANGIAL CELL PROLIFERATION AND MATRIX EXPANSION. *J Biol Chem*. 2001;276(52):49142-49147. doi:10.1074/JBC.M104879200

46. Kahraman S, Kiykim AA, Altun B, et al. Apolipoprotein E gene polymorphism in renal transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function. *Clin Transplant*. 2004;18(3):288-294. doi:10.1111/j.1399-0012.2004.00162.x

47. Hernández D, Salido E, Linares J, et al. Role of apolipoprotein E epsilon 4 allele on chronic allograft nephropathy after renal transplantation. *Transplant Proc*. 2004;36(10):2982-2984. doi:10.1016/j.transproceed.2004.10.038

48. Cofán F, Cofan M, Rosich E, et al. Effect of apolipoprotein E polymorphism on renal transplantation. *Transplant Proc*. 2007;39(7):2217-2218. doi:10.1016/j.transproceed.2007.06.011

49. Czaplińska M, Ćwiklińska A, Sakowicz-Burkiewicz M, et al. Apolipoprotein e gene polymorphism and renal function are associated with apolipoprotein e concentration in patients with chronic kidney disease. *Lipids Health Dis*. 2019;18(1):1-9. doi:10.1186/s12944-019-1003-x

50. Hsu CC, Kao WHL, Coresh J, et al. Apolipoprotein E and progression of chronic kidney
disease. *J Am Med Assoc*. 2005;293(23):2892-2899. doi:10.1001/jama.293.23.2892

51. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E
mutations in lipoprotein glomerulopathy. *Trends Cardiovasc Med*. 2002;12(2):67-70.
doi:10.1016/S1050-1738(01)00148-7

52. Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in
human iPSC-derived glia. *Sci Transl Med*. 2021;13(583):eaaz4564.
doi:10.1126/scitranslmed.aaz4564

53. Huang H, van Dullemen LFA, Akhtar MZ, et al. Proteo-metabolomics reveals compensation
between ischemic and non-injured contralateral kidneys after reperfusion. *Sci Rep*.
2018;8(1):8539. doi:10.1038/s41598-018-26804-8

54. Zhao H, Ji Q, Wu Z, et al. Destabilizing heterochromatin by APOE mediates senescence.
Nature Aging. 2022;2(4):303-316. doi:10.1038/s43587-022-00186-z

55. Julian BA, Gaston RS, Brown WM, et al. Effect of Replacing Race with Apolipoprotein L1
Genotype in Calculation of Kidney Donor Risk Index. *Am J Transplant*. 2017;17(6):1540.
doi:10.1111/AJT.14113

56. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive
estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J
Kidney Dis*. 2000;36(1):29-34. doi:10.1053/ajkd.2000.8237

57. Christensson A, Ekberg J, Grubb A, Ekberg H, Lindström V, Lilja H. Serum cystatin C is a
more sensitive and more accurate marker of glomerular filtration rate than enzymatic
measurements of creatinine in renal transplantation. *Nephron Physiol*. 2003;94(2):19-27.
doi:10.1159/000071287

58. Rodrigo E, Ruiz JC, Fernández-Fresnedo G, et al. Cystatin C and albuminuria as predictors
of long-term allograft outcomes in kidney transplant recipients. *Clin Transplant*.
2013;27(2):E177-83. doi:10.1111/ctr.12082

59. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C--a
new marker of glomerular filtration rate in children independent of age and height.
Pediatrics. 1998;101(5):875-881. doi:10.1542/peds.101.5.875

60. Edinga-Melenge BE, Yakam AT, Nansseu JR, et al. Reference intervals for serum cystatin C
and serum creatinine in an adult sub-Saharan African population. *BMC Clin Pathol*.
2019;19:4. doi:10.1186/s12907-019-0086-7

61. Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method integrating
quantitative proteomics with complementary high-throughput data. *BMC Bioinformatics*.
2012;13(16):S12. doi:10.1186/1471-2105-13-S16-S12

62. Oberbauer R, Rohrmoser M, Regele H, Mühlbacher F, Mayer G. Apoptosis of tubular
epithelial cells in donor kidney biopsies predicts early renal allograft function. *J Am Soc
Nephrol*. 1999;10(9):2006-2013. doi:10.1681/ASN.V1092006

63. Heyman SN, Rosenberger C, Rosen S. Experimental ischemia-reperfusion: biases and
myths-the proximal vs. distal hypoxic tubular injury debate revisited. *Kidney Int*.
2010;77(1):9-16. doi:10.1038/ki.2009.347

64. Gobe GC, Johnson DW. Distal tubular epithelial cells of the kidney: Potential support for
proximal tubular cell survival after renal injury. *Int J Biochem Cell Biol*. 2007;39(9):1551-
1561. doi:10.1016/j.biocel.2007.04.025

65. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin
in Patients with Chronic Kidney Disease. *N Engl J Med*. 2023;388(2):117-127.
doi:10.1056/NEJMoa2204233

66. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
ageing. *Nat Rev Genet*. 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3

67. Meier F, Brunner AD, Frank M, et al. diaPASEF: parallel accumulation–serial fragmentation
combined with data-independent acquisition. *Nat Methods*. 2020;17(12):1229-1236.
doi:10.1038/s41592-020-00998-0

68. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and
resources in 2019: improving support for quantification data. *Nucleic Acids Res*.
2019;47(D1):D442-D450. doi:10.1093/nar/gky1106

ACKNOWLEDGMENTS

We thank the UK QUOD Consortium and NHS Blood and Transplant UK Registry for providing

the samples and the associated clinical and demographic metadata. ; in particular we thank Sheba

Ziyenge, Lewis Simmonds and Dr Sarah Cross, Dr Sergei Maslau and Mr Tomas Surik for their

support on the QUOD sample selection.

We thank members of the Discovery Proteomics Facility within the TDI Mass Spectrometry

Laboratory for expert help with mass spectrometry analysis, and members of the Lindgren group

at the BDI for informative discussions regarding statistical modelling.

824
Figure 1: Experimental design to discover donor kidney proteome associations with transplant outcome
We selected biopsies from QUOD biobank taken from one kidney from each donor pair. Donor kidney samples
were selected randomly from pairs where both recipients had similar outcomes. The biopsy samples were subjected
to proteomic analysis to yield a snapshot of the organ proteome at kidney retrieval. We analyzed donor
characteristics and clinical variables and protein abundances in a combined model against recipient eGFR at 12
months posttransplant (eGFR12; units given in ml/min/1.73 m^2).

Donor Type	DBD			DCD		
12m Outcome Tertile ml/min/1.73 m^2	Lower eGFR<40	Intermediate 40≤eGFR<60	Upper eGFR≥60	Lower eGFR<40	Intermediate 40≤eGFR≤60	Upper eGFR≥60
n	31	31	38	31	28	26
Donor Age, y	56.84 ± 12.29	51.32 ± 12.24	39.05 ± 14.12	55.48 ± 9.34	53.57 ± 9.75	38.31 ± 12.28
Donor Sex						
Male	15 (48.4%)	16 (51.6%)	19 (50.0%)	22 (71.0%)	16 (57.1%)	16 (61.5%)
Female	16 (51.6%)	15 (48.4%)	19 (50.0%)	9 (29.0%)	12 (42.9%)	10 (38.5%)
Donor Ethnicity						
White	30 (96.8%)	30 (96.8%)	36 (94.7%)	30 (96.8%)	28 (100.0%)	25 (96.2%)
Other	1 (3.2%)	1 (3.2%)	2 (5.3%)	1 (3.2%)	0 (0.0%)	1 (3.8%)
Donor Weight, kg	82.53 ± 18.20	76.61 ± 18.07	81.38 ± 17.72	80.58 ± 14.95	82.43 ± 17.20	78.67 ± 13.96
Donor Height, cm	168.42 ± 9.37	169.52 ± 7.67	174.82 ± 11.16	169.97 ± 7.98	171.64 ± 9.73	174.65 ± 8.98
Donor S-Cr terminal, µmol/l	86.54 ± 40.81	82.57 ± 49.65	90.19 ± 67.36	73.37 ± 19.03	70.31 ± 39.02	59.60 ± 22.39
Donor CIT, h	15.80 ± 3.88	14.20 ± 4.60	13.42 ± 4.67	13.65 ± 5.20	11.72 ± 3.55	12.80 ± 4.49
Donor COD						
Trauma	1 (3.2%)	3 (9.7%)	3 (7.9%)	4 (12.9%)	3 (10.7%)	4 (15.4%)
Other	30 (96.8%)	28 (90.3%)	35 (92.1%)	27 (87.1%)	25 (89.3%)	22 (84.6%)
Donor UKKDRI	1.41 ± 0.52	1.10 ± 0.36	0.85 ± 0.36	1.31 ± 0.37	1.21 ± 0.40	0.73 ± 0.35
Recipient Age, y	53.03 ± 12.21	52.10 ± 14.61	39.71 ± 16.03	51.90 ± 9.85	50.93 ± 11.04	44.92 ± 12.87
Recipient Sex						
Female	15 (48.4%)	8 (25.8%)	12 (31.6%)	11 (35.5%)	9 (32.1%)	5 (19.2%)
Male	16 (51.6%)	23 (74.2%)	26 (68.4%)	20 (64.5%)	19 (67.9%)	21 (80.8%)
Recipient Ethnicity						
White	24 (77.4%)	21 (67.7%)	29 (76.3%)	22 (71.0%)	23 (82.1%)	20 (76.9%)
Other	7 (22.6%)	10 (32.3%)	9 (23.7%)	9 (29.0%)	5 (17.9%)	6 (23.1%)
Recipient Posttransplant Kidney Function (mean eGFR, ml/min/1.73 m^2)						
3 months	29.71 ± 12.06	50.32 ± 17.28	78.54 ± 25.97	31.72 ± 12.24	46.50 ± 10.34	77.88 ± 18.57
12 months	26.58 ± 11.98	49.58 ± 6.10	85.58 ± 35.84	25.10 ± 12.01	48.24 ± 6.29	80.26 ± 15.91
HLA Mismatch Groups						
0 Mismatches	3 (10.0%)	4 (11.4%)	9 (25.7%)	1 (2.9%)	1 (4.2%)	0 (0.0%)
0 DR and 0/1 B	7 (23.3%)	13 (37.1%)	10 (28.6%)	10 (28.6%)	6 (25.0%)	8 (30.8%)
0 DR and 2 B or 1 DR and 0/1 B	17 (56.7%)	14 (40.0%)	13 (37.1%)	21 (60.0%)	14 (58.3%)	14 (53.8%)
1 DR and 2 B or 2 DR	3 (10.0%)	4 (11.4%)	3 (8.6%)	3 (8.6%)	3 (12.5%)	4 (15.4%)

831 **Table 1: Donor and recipient clinical and demographic variables**
832 Donor kidney associated metadata. Samples are subdivided by donor type and by final assigned outcome tertile.
833 Numerical variables are given ± standard deviation. Categorial variables are given alongside percentage of total
834 cohort

A

B

Figure 2: Proteins predicting transplant outcome show immuno-metabolic functional associations, predict
low eGFR outcomes and are consistent with Western Blot assay results.
A: Shared Reactome pathway membership network analysis of filtered features. Nodes are colored by assigned
cluster, and the clusters are annotated according to the top three most enriched pathways within each cluster.
B: Western blots comparing younger (age $\leq$ 49; mean age 34) and older (age $\geq$ 58; mean age 64) donors between
Upper Tertile (UT; eGFR12 $\geq$ 60) and Lower Tertile (LT; eGFR12 < 40) outcomes. As above, Left-Right: VTN,
APOE, CST3. Top row: representative western blots (n=5 per group) from comparison of younger donors. Middle
row: representative western blots (n=5 per group) from comparison of older donors. Bottom row: result values for
all quantified samples relative to the UT mean. UT values in green, LT values in blue. Error bars indicate $\pm$1
standard deviation; the central wider bar indicates mean. Significance stars indicate t-test comparison p-values (***:
$p < 0.001$, *: $p < 0.05$).
All eGFR12 units given in ml/min/1.73 m^2

Cluster Label	Top 3 Shared Pathways
Immune Regulation & Complement Activation	Immune System Innate Immune System Regulation of Complement Cascade
Protein Metabolism and Regulation	Metabolism of Proteins Post-translational Protein Modification Post-translational Protein Phosphorylation
Metabolism	Metabolism Metabolism of Amino Acids and Derivatives Retinoid Metabolism and Transport
Cell Cycle	Cyclin E Associated Events During G1/S Transition Cyclin A:Cdk2-associated Events at S Phase Entry PCP/CE Pathway

848 **Table 2: Major Shared Pathway Network Clusters**
849 Proteins in Figure 2A were clustered by pathway membership, forming 4 major clusters (those with more than a
850 single member). We assigned summary labels to each cluster based on the top 3 pathways with shared membership
851 in each cluster.

852
Figure 3: Modelled associations between proteins and kidney transplant outcome change with donor age
Our modelling found that the effect of candidate protein levels on outcome changed with age.
A: We quantile-normalized protein levels to a consistent scale and predicted outcome (12-month posttransplant
eGFR) across a representative donor age range. Using this prediction matrix to compare the interaction with age
between protein models, we found 3 major clusters (Left-Right; blue, pink and green dendrogram branches and
corresponding plot background color) representing increasing levels of age modulation. Moving Left-Right across
each plot, the eGFR12 (color scale, see key on right) contours across protein quantile (y axis) change as donor age
(x axis) increases.
B: Illustrative protein quantile-GFR12 plots are shown for each three proteins in each cluster. Traces are shown for
donor ages between 20 and 80 as labelled on the right end of each trace.

Lower AKI:CKD Correlation in Selected Genes vs Background; -log10(p-value)

Figure 4: Independent scRNA-seq Data Indicate Spatial Localization of the Outcome-Associated Signature
We reasoned that proteins/genes which predict outcome should associate with specific facets of organ injury rather
than general inflammatory and stress response, and therefore would be expected to have a *lower* expression
correlation between acute and chronic damage scenarios than non-predictive other proteins/genes. We explored this
in a spatially resolved public transcriptomic dataset and found that the degree of correlation was significantly lower
for the set of 144 candidate predictors identified by our modelling approach, but that the signal appears to be
spatially localized, primarily to distal convoluted tubule epithelial cells and the epithelia of neighboring tubules
(indicated by red highlighting in right hand diagram).